DC Field | Value | Language |
---|---|---|
dc.contributor.author | D Lim | - |
dc.contributor.author | K S Kim | - |
dc.contributor.author | H J Kim | - |
dc.contributor.author | Kyong-Cheol Ko | - |
dc.contributor.author | Jae Jun Song | - |
dc.contributor.author | Jong Hyun Choi | - |
dc.contributor.author | M Shin | - |
dc.contributor.author | J J Min | - |
dc.contributor.author | J H Jeong | - |
dc.contributor.author | H E Choy | - |
dc.date.accessioned | 2017-08-29 | - |
dc.date.available | 2017-08-29 | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 19492553 | - |
dc.identifier.uri | 10.18632/oncotarget.17197 | ko |
dc.identifier.uri | https://oak.kribb.re.kr/handle/201005/17193 | - |
dc.description.abstract | The anticancer strategy underlying the use of immunotoxins is as follows: the cancer-binding domain delivers the toxin to a cancer cell, after which the toxin enters and kills the cell. TGFα-PE38 is an immunotoxin comprising transforming growth factor alpha (TGFα), a natural ligand of epidermal growth factor receptor (EGFR), and a modified Pseudomonas exotoxin A (PE38) lacking N terminal cell-binding domain, a highly potent cytotoxic protein moiety. Tumor cells with high level of EGFR undergo apoptosis upon treatment with TGFα-PE38. However, clinical trials demonstrated that this immunotoxin delivered by an intracerebral infusion technique has only a limited inhibitory effect on intracranial tumors mainly due to inconsistent drug delivery. To circumvent this problem, we turned to tumor-seeking bacterial system. Here, we engineered Salmonella typhimurium to selectively express and release TGFα-PE38. Engineered bacteria were administered to mice implanted with mouse colon or breast tumor cells expressing high level of EGFR. We observed that controlled expression and release of TGFα-PE38 from intra-tumoral Salmonellae by either an engineered phage lysis system or by a bacterial membrane transport signal led to significant inhibition of solid tumor growth. These results demonstrated that delivery by tumor-seeking bacteria would greatly augment efficacy of immunotoxin in cancer therapeutics | - |
dc.publisher | Impact Journals | ko |
dc.title | Anti-tumor activity of an immunotoxin (TGFα-PE38) delivered by attenuated Salmonella typhimurium | - |
dc.title.alternative | Anti-tumor activity of an immunotoxin (TGFα-PE38) delivered by attenuated Salmonella typhimurium | - |
dc.type | Article | - |
dc.citation.title | Oncotarget | - |
dc.citation.number | 23 | - |
dc.citation.endPage | 37560 | - |
dc.citation.startPage | 37550 | - |
dc.citation.volume | 8 | - |
dc.contributor.affiliatedAuthor | Kyong-Cheol Ko | - |
dc.contributor.affiliatedAuthor | Jae Jun Song | - |
dc.contributor.affiliatedAuthor | Jong Hyun Choi | - |
dc.contributor.alternativeName | 임대진 | - |
dc.contributor.alternativeName | 김광수 | - |
dc.contributor.alternativeName | 김현주 | - |
dc.contributor.alternativeName | 고경철 | - |
dc.contributor.alternativeName | 송재준 | - |
dc.contributor.alternativeName | 최종현 | - |
dc.contributor.alternativeName | 신민상 | - |
dc.contributor.alternativeName | 민정준 | - |
dc.contributor.alternativeName | 정재호 | - |
dc.contributor.alternativeName | 최현 | - |
dc.identifier.bibliographicCitation | Oncotarget, vol. 8, no. 23, pp. 37550-37560 | - |
dc.identifier.doi | 10.18632/oncotarget.17197 | - |
dc.subject.keyword | Bacterial cancer therapy | - |
dc.subject.keyword | Immunotoxin | - |
dc.subject.keyword | Salmonella | - |
dc.subject.keyword | TGFα-PE38 | - |
dc.subject.local | Bacterial cancer therapy | - |
dc.subject.local | Immunotoxin | - |
dc.subject.local | Salmonella | - |
dc.subject.local | TGFα-PE38 | - |
dc.description.journalClass | N | - |
There are no files associated with this item.
Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.